Form D · Biotechnology

TheraCell, Inc.

Northridge, CA · CIK 0001502547

Offering snapshot reported Mar 17, 2015 · SEC filing

Reported sold
$75K
Offering amount: $3M
Investors reported
3
Form D · investor count
Minimum accepted
$10K
Reported outside-investor minimum
First sale
Mar 16, 2015
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Mar 17, 2015Initial$75,000No comparison3SEC filing
Oct 1, 2010Initial$1,344,000No comparison25SEC filing

Offering details

Securities
Equity
Exemptions
06c
Duration over one year
No
Business combination
No
Sales commissions
$0 (estimated)
Finders' fees
$0
Form D file number
021-236032
FlashFunders Securities, LLC receives a right of first refusal up to the number equal to ten percent of the amount of securities sold in the next qualified financing.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
FlashFunders Securities, LLC134742

Source: Form D, filed Mar 17, 2015. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Andrew Carter Executive
Danny Gazit Director
Richard K. Grant Director, Executive
Jan Iwanczyk Director
Joseph Miller Director
Bradley Patt Director, Executive
Frank Phillips Director
Nelson Scarborough Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
19355 Business Center Drive Suite 9
Northridge, CA, 91324